NCT05598814View on ClinicalTrials.gov

Mepolizumab to CRSwNP Through 12 Months - Randomised to FESS and Non-FESS Within the First 2 Weeks

PHASE4Active, not recruitingINTERVENTIONAL
Enrollment

58

Participants

Timeline

Start Date

April 1, 2023

Primary Completion Date

August 31, 2024

Study Completion Date

August 31, 2025

Conditions
Chronic Rhinosinusitis with Nasal PolypsAsthma
Interventions
BIOLOGICAL

Mepolizumab Injection

All patients in both the intervention group and the control group will be treated with Mepolizumab injections every month.

PROCEDURE

Functional Endoscopic Sinus Surgery (FESS).

The Functional Endoscopic Sinus Surgery will be performed 2 weeks after the first injection of Mepolizumab in the intervention group.

Trial Locations (1)

2100

Rigshospitalet, Department of Otorhinolaryngology, Head and Neck Surgery & Audiology, Copenhagen

All Listed Sponsors
lead

Vibeke Backer

OTHER